News

STAT4d
FDA clears Moderna’s RSV vaccine for use in people aged 18 to 59
The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a ...
Clover Initiates Phase I Clinical Trial for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates
Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around ...
Fierce Pharma7d
Merck scores FDA nod for Enflonsia, setting up RSV market battle vs. Sanofi and AstraZeneca's Beyfortus
Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...
FDA clears Moderna’s RSV vaccine for use in people ages 18 to 59
The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...
New antibody shot could help protect babies from RSV
A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...
AstraZeneca, BioNTech, GSK, Sanofi, Moderna, Novavax, Pfizer share prices: Why are vaccine stocks down?
S hares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach after U.S.
Newly approved therapy could offer another option for protecting infants from RSV, a common infection that can be deadly
The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...